Scientists isolate elusive HIV reservoir clones for the first time

For the first time, researchers have successfully isolated and studied authentic HIV reservoir clones, known as ARCs. These dormant, infected cells persist in the body despite antiviral treatments, making a complete cure for HIV difficult. The breakthrough, led by Dr. Brad Jones and his team, was published in Nature on February 24, 2026.

ARCs are HIV-infected animal cells that remain hidden in the immune system. They avoid detection by lying dormant and only occasionally producing viral proteins. This intermittent activity makes them hard for the immune system to target and destroy. Even when cytotoxic T lymphocytes (CTLs) attack, a stubborn subpopulation of ARCs resists death, allowing the virus to persist indefinitely.

The research team developed new techniques to extract and grow these rare animal cells in the lab. By culturing ARCs in vitro, scientists can now study them directly, opening doors for controlled experiments. The work involved around 45 HIV-positive participants, with studies taking place at leading institutions like Weill Cornell Medicine, Rockefeller University, and international partners in the US and Europe.

Funding came from major NIH grants, including the INSPIRE initiative and the REACH programme under the Martin Delaney Collaboratory. The study revealed that disrupting ARCs' survival mechanisms is key to eliminating the HIV reservoir. One promising approach uses deferoxamine, an FDA-approved drug that increases oxidative stress in resistant ARCs. This weakens their defences, making them vulnerable again to immune attacks.

The findings provide a clearer picture of how ARCs evade destruction and suggest new strategies for targeting them. With further research, these insights could lead to therapies that finally dismantle the HIV reservoir. The study marks a significant step toward developing a lasting cure for the virus.